• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Northwest Kidney Centers and Outset Medical Announce Collaboration to Grow Home Hemodialysis

    9/3/25 9:00:00 AM ET
    $OM
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $OM alert in real time by email

    SAN JOSE, Calif., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Northwest Kidney Centers, the first organization to establish a home hemodialysis program, today announced a collaboration with Outset Medical, Inc. (NASDAQ:OM) ("Outset"), a medical technology company transforming the dialysis experience across the continuum of care. Through the collaboration, Northwest Kidney Centers will add Outset's Tablo Hemodialysis System to its offerings for patients in its network with the shared goal to expand access to home hemodialysis. With one of the largest and oldest home dialysis programs in the country, Northwest Kidney Centers has long championed patient independence and flexibility. Currently, nearly 20% of its patients dialyze at home, supported by personalized training, 24/7 nursing access, and in-home care. The addition of Tablo to its home program marks a significant step forward in making dialysis more accessible, intuitive, and aligned with modern lifestyles.

    "Northwest Kidney Centers has long prioritized patient independence and long-term success in home dialysis," said Matthew Rivara, MD, Chief Medical Officer at Northwest Kidney Centers. "Our collaboration with Outset Medical and the integration of Tablo into our home program supports our commitment to innovation and patient-centered care. Patients who have used the Tablo system during our pilot phase report its intuitive design and ease of training have helped them stay engaged and confident in their treatment, which directly contributes to optimal quality of life for patients and the ability to continue to treat at home."

    Tablo is designed to operate with just tap water and a standard electrical outlet, eliminating the need for complex infrastructure. Its touchscreen interface, automated setup, and cloud-connected ecosystem make it easy to learn and use—by providers and patients.

    "Tablo was built to simplify and reduce the burden of dialysis making it more accessible to patients," said Michael Aragon, MD, Chief Medical Officer at Outset Medical. "We're proud to collaborate with Northwest Kidney Centers, whose thought leadership in home dialysis is widely recognized, and aligns with our mission to innovate for better patient experiences and long-term success."

    This collaboration reflects a shared commitment to improving lives through not just technology, but through meaningful, community-rooted care. By bringing Tablo's innovative home dialysis system to patients in the Puget Sound region, Northwest Kidney Centers and Outset Medical are expanding access to treatment that is easier to learn, more sustainable, and better aligned with patients' daily lives.

    Together, the organizations are helping more people live healthier, more independent lives at home, with dignity and confidence. As leaders in kidney care and innovation, Northwest Kidney Centers and Outset Medical are proud to support a future where dialysis is not only more accessible, but more empowering for every patient and family they serve.

    About Northwest Kidney Centers

    Northwest Kidney Centers is a nonprofit, community-based provider of kidney dialysis, public health education and research into the causes and treatments of chronic kidney disease. Founded in Seattle in 1962, it was the world's first outpatient dialysis organization and today is the eighth-largest dialysis provider in the United States, serving more than 2,000 patients a year in 19 dialysis centers and eight hospitals in the Puget Sound region.

    Northwest Kidney Centers' mission is to promote the optimal health, quality of life and independence of people with kidney disease. Its patients have access to the first-in-the-nation kidney palliative care program, as well as an outpatient pharmacy staffed by kidney specialists. Through its long-standing partnership with the University of Washington, Northwest Kidney Centers helped establish the Kidney Research Institute in support of discoveries to better patients' lives. For more information, visit www.nwkidney.org.

    Contact

    Stephanie Pitts

    206-720-8510

    About Outset Medical, Inc. 

    Outset is a medical technology company transforming the dialysis experience across the continuum of care with a first-of-its-kind technology. The Tablo® Hemodialysis System, FDA-cleared for use from hospital to home, is trusted by more than 1,000 U.S. healthcare facilities and has enabled millions of treatments delivered by thousands of nurses. Designed to reduce the cost and complexity of dialysis, Tablo combines water purification and on-demand dialysate production into a single, integrated system that connects seamlessly with Electronic Medical Record systems and a proprietary data analytics platform. This enterprise solution empowers providers to develop an in-house dialysis program where they are in control – enabling better operational, clinical, and financial outcomes. Outset is redefining what's possible in kidney care through innovation, scale, and a relentless commitment to improving the lives of patients and the professionals who care for them. For more information, visit www.outsetmedical.com.

    Contact

    Jim Mazzola

    [email protected]



    Get the next $OM alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $OM

    DatePrice TargetRatingAnalyst
    8/8/2024$6.00 → $3.00Outperform → Sector Perform
    RBC Capital Mkts
    6/21/2024$5.00 → $6.00Sector Perform → Outperform
    RBC Capital Mkts
    4/8/2024$6.00Buy
    BTIG Research
    4/5/2024$6.00Neutral → Buy
    CL King
    1/12/2024$14.00 → $6.00Outperform → Sector Perform
    RBC Capital Mkts
    10/13/2023$32.00 → $3.00Buy → Underperform
    BofA Securities
    8/17/2023Neutral
    CL King
    11/11/2022$23.00Outperform
    RBC Capital Mkts
    More analyst ratings

    $OM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Outset Medical downgraded by RBC Capital Mkts with a new price target

    RBC Capital Mkts downgraded Outset Medical from Outperform to Sector Perform and set a new price target of $3.00 from $6.00 previously

    8/8/24 6:47:35 AM ET
    $OM
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Outset Medical upgraded by RBC Capital Mkts with a new price target

    RBC Capital Mkts upgraded Outset Medical from Sector Perform to Outperform and set a new price target of $6.00 from $5.00 previously

    6/21/24 6:53:06 AM ET
    $OM
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    BTIG Research initiated coverage on Outset Medical with a new price target

    BTIG Research initiated coverage of Outset Medical with a rating of Buy and set a new price target of $6.00

    4/8/24 7:26:20 AM ET
    $OM
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $OM
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Northwest Kidney Centers and Outset Medical Announce Collaboration to Grow Home Hemodialysis

    SAN JOSE, Calif., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Northwest Kidney Centers, the first organization to establish a home hemodialysis program, today announced a collaboration with Outset Medical, Inc. (NASDAQ:OM) ("Outset"), a medical technology company transforming the dialysis experience across the continuum of care. Through the collaboration, Northwest Kidney Centers will add Outset's Tablo Hemodialysis System to its offerings for patients in its network with the shared goal to expand access to home hemodialysis. With one of the largest and oldest home dialysis programs in the country, Northwest Kidney Centers has long championed patient independence and flexibility. Currently, nearly

    9/3/25 9:00:00 AM ET
    $OM
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Outset Medical to Present at the 23rd Annual Morgan Stanley Global Healthcare Conference

    SAN JOSE, Calif., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (NASDAQ:OM) ("Outset"), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today announced that management will present at the 23rd annual Morgan Stanley Global Healthcare Conference on Wednesday, Sept. 10, 2025, at 7 a.m. Eastern time. A live and archived webcast of the presentation will be available on the "Investors" section of the Outset website at https://investors.outsetmedical.com/. About Outset Medical, Inc. Outset is a medical technology company transforming the dialysis experience across the continuum of care with a first-of-its-kind techno

    8/20/25 4:05:00 PM ET
    $OM
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Outset Medical Second-Quarter Results Demonstrate Continued Momentum, Punctuated by Strong Revenue Growth, Console Placements and Utilization

    SAN JOSE, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (NASDAQ:OM), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today reported financial results for the second quarter ended June 30, 2025. Second Quarter and Recent Highlights Net revenue of $31.4 million grew 15% from the prior-year period, driven by a 25% increase in Tablo console revenue.Recurring revenue consisting of Tablo consumables and services grew 11% over the prior-year period to $22.5 million, driven by a 17% increase in consumable revenue.Gross margin was 37.8%, or 38.4% on a non-GAAP basis, a 110 basis-point improvement over the prior

    8/6/25 4:02:00 PM ET
    $OM
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $OM
    SEC Filings

    View All

    SEC Form 144 filed by Outset Medical Inc.

    144 - Outset Medical, Inc. (0001484612) (Subject)

    8/15/25 7:57:18 PM ET
    $OM
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Outset Medical Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Outset Medical, Inc. (0001484612) (Filer)

    8/6/25 4:15:10 PM ET
    $OM
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form SCHEDULE 13G filed by Outset Medical Inc.

    SCHEDULE 13G - Outset Medical, Inc. (0001484612) (Subject)

    7/29/25 2:14:28 PM ET
    $OM
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $OM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP, R&D, Operations and Serv. Nash Marc was granted 5,617 shares, increasing direct ownership by 13% to 48,515 units (SEC Form 4)

    4 - Outset Medical, Inc. (0001484612) (Issuer)

    8/25/25 7:59:58 PM ET
    $OM
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Chair and CEO Trigg Leslie sold $11,644 worth of shares (904 units at $12.88), decreasing direct ownership by 0.73% to 122,328 units (SEC Form 4)

    4 - Outset Medical, Inc. (0001484612) (Issuer)

    8/18/25 4:05:30 PM ET
    $OM
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SVP Operations and R&D Nash Marc sold $3,130 worth of shares (243 units at $12.88), decreasing direct ownership by 0.56% to 42,898 units (SEC Form 4)

    4 - Outset Medical, Inc. (0001484612) (Issuer)

    8/18/25 4:01:44 PM ET
    $OM
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $OM
    Leadership Updates

    Live Leadership Updates

    View All

    Outset Medical Appoints Industry Veteran Kevin O'Boyle to its Board of Directors

    SAN JOSE, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (NASDAQ:OM) ("Outset"), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today announced the appointment of healthcare industry veteran Kevin O'Boyle to its Board of Directors and as chair of its Audit Committee. With Mr. O'Boyle's appointment, the company also announced that Dale E. Jones has stepped down from the Board. "Kevin's over 20 years of healthcare leadership experience span roles as CFO of several publicly traded companies and as a board director of 6 public medical device companies," said Leslie Trigg, Chair and CEO. "His expertise in c

    5/14/25 9:00:00 AM ET
    $OM
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Masimo Announces Leadership Transition

    Katie Szyman Appointed Chief Executive Officer and to Board of Directors Interim CEO Michelle Brennan Named Chairman of Masimo's Board Today the Board of Directors (the "Board") of Masimo (NASDAQ:MASI), a leading global medical innovator, announced that Katie Szyman has been appointed the next Chief Executive Officer ("CEO") of the Company. Interim CEO Michelle Brennan has been appointed Chairman of Masimo's Board and Lead Independent Director Quentin Koffey has been appointed Vice Chairman. All of these changes are effective as of February 12, 2025. Ms. Szyman is currently worldwide president of Advanced Patient Monitoring at BD (Becton, Dickinson and Company). Previously, Ms. Szyman

    1/21/25 4:00:00 PM ET
    $MASI
    $NARI
    $OM
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Medical/Dental Instruments

    Outset Medical Names Business Leader Dale E. Jones to Board of Directors

    Outset Medical, Inc. (NASDAQ:OM) ("Outset"), a medical technology company reducing the cost and complexity of dialysis, today announced the appointment of Dale E. Jones to its Board of Directors. "Dale brings more than 30 years of experience in building diverse and dynamic teams to Outset at a time of exceptional growth for our team," said Chair and CEO Leslie Trigg. "He leads with purpose and deeply understands the role values and culture play in building high-performance organizations, critical traits as we focus on transforming dialysis." Mr. Jones is a Senior Advisor at Diversified Search Group, and previously served as its CEO for more than eight years. He began his career in banking

    4/25/22 4:00:00 PM ET
    $OM
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $OM
    Financials

    Live finance-specific insights

    View All

    Outset Medical Second-Quarter Results Demonstrate Continued Momentum, Punctuated by Strong Revenue Growth, Console Placements and Utilization

    SAN JOSE, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (NASDAQ:OM), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today reported financial results for the second quarter ended June 30, 2025. Second Quarter and Recent Highlights Net revenue of $31.4 million grew 15% from the prior-year period, driven by a 25% increase in Tablo console revenue.Recurring revenue consisting of Tablo consumables and services grew 11% over the prior-year period to $22.5 million, driven by a 17% increase in consumable revenue.Gross margin was 37.8%, or 38.4% on a non-GAAP basis, a 110 basis-point improvement over the prior

    8/6/25 4:02:00 PM ET
    $OM
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Outset Medical to Report Second Quarter 2025 Financial Results on Wednesday, August 6, 2025

    SAN JOSE, Calif., July 16, 2025 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (NASDAQ:OM) ("Outset"), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today announced that it will release financial results for the second quarter 2025 after the close of trading on Wednesday, August 6, 2025. On the same day, at 2:00 p.m. Pacific time (5:00 p.m. Eastern time), Leslie Trigg, Chair and Chief Executive Officer, and Renee Gaeta, Chief Financial Officer, will host a conference call to discuss financial and operating results. Conference Call DetailsThe conference call will begin at 2:00 p.m. Pacific time (5:00 p.m. Eastern time) on W

    7/16/25 4:03:00 PM ET
    $OM
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Outset Medical First-Quarter Results Demonstrate Strong Growth in Console and Recurring Revenue as Gross Margin Expanded and Cash Use Declined

    SAN JOSE, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (NASDAQ:OM), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today reported financial results for the first quarter ended March 31, 2025. First Quarter and Recent Highlights Net revenue of $29.8 million grew 6% from the prior-year period.Tablo console revenue grew 23% from the fourth quarter.Recurring revenue consisting of Tablo consumables and services grew 20% over the prior-year period to $22.7 million. Outset shipped its 3 millionth Tablo treatment during the quarter, adding 1 million treatments over a period of approximately 12 months.Gross ma

    5/7/25 4:02:00 PM ET
    $OM
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $OM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Outset Medical Inc.

    SC 13G/A - Outset Medical, Inc. (0001484612) (Subject)

    11/12/24 4:53:46 PM ET
    $OM
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Amendment: SEC Form SC 13G/A filed by Outset Medical Inc.

    SC 13G/A - Outset Medical, Inc. (0001484612) (Subject)

    11/12/24 4:26:01 PM ET
    $OM
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Amendment: SEC Form SC 13G/A filed by Outset Medical Inc.

    SC 13G/A - Outset Medical, Inc. (0001484612) (Subject)

    11/12/24 10:32:13 AM ET
    $OM
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care